Disclosures for "Rationale, Patient Characteristics, and First Interim Insights from NeofiLos – A Prospective Data Collection to Evaluate Utility and Added Value of Serum NfL in MS"
-
Katja Akgün has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Katja Akgün has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Katja Akgün has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Katja Akgün has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Katja Akgün has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Katja Akgün has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Katja Akgün has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Katja Akgün has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS.
-
Ulf Schulze Topphoff has received personal compensation for serving as an employee of Novartis Pharma GmbH.
-
Katrin Schuh has received personal compensation for serving as an employee of Novartis Pharma GmbH.
-
Dr. Schwab Sauerbeck has received personal compensation for serving as an employee of Novartis Germany IMI.
-
Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS Celgene. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS Celgene. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. The institution of Dr. Ziemssen has received research support from Biogen. The institution of Dr. Ziemssen has received research support from Novartis. The institution of Dr. Ziemssen has received research support from Merck. The institution of Dr. Ziemssen has received research support from Sanofi. The institution of Dr. Ziemssen has received research support from Celgene.